Condition: Fabry Disease · Sponsor: UniQure Biopharma B.V.
The main goals of this clinical study are to characterize safety and PK/PD of AMT-191 i.e. if drug doses used in the study are safe and tolerable and to understand how it acts in the body of people with Fabry disease.
This description comes directly from the study's public registry record.
uniQure · 1-866-520-1257 · medinfo@uniqure.com
Christy Quintana · 734-680-7773 · medinfo@uniqure.com
Always discuss trial participation with your own doctor first.
| The Kirklin Clinic Of university of Alabama Birmingham Hospital | Birmingham, Alabama, United States | Recruiting |
| Emory University School of Medicine | Atlanta, Georgia, United States | Recruiting |
| Ann & Robert H. Lurie Children's Hospital of Chicago | Chicago, Illinois, United States | Recruiting |
| MHealth Fairview University of Minnesota Medical Center East Bank | Minneapolis, Minnesota, United States | Recruiting |
| NYC Health + Hospitals/Metropolitan | New York, New York, United States | Recruiting |
| UPMC Children's Hospital of Pittsburgh | Pittsburgh, Pennsylvania, United States | Recruiting |
| University of Utah, Clinical and Translational Sciences Institute | Salt Lake City, Utah, United States | Recruiting |
| Lysosomal & Rare Disorders Research and Treatment Center, Inc | Fairfax, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06270316